Trials & Approvals
Tecentriq/Arbaxane Combo Becomes the First FDA Approved Immunotherapy Regimen for Breast Cancer Treatment
2019-03-14
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28